Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Holdings Boosted by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) by 6.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 370,472 shares of the company’s stock after purchasing an additional 23,974 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.60% of Monte Rosa Therapeutics worth $2,571,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of GLUE. Geode Capital Management LLC lifted its stake in Monte Rosa Therapeutics by 23.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,044,689 shares of the company’s stock worth $5,538,000 after acquiring an additional 197,247 shares in the last quarter. Barclays PLC lifted its position in shares of Monte Rosa Therapeutics by 395.1% in the third quarter. Barclays PLC now owns 54,508 shares of the company’s stock worth $289,000 after purchasing an additional 43,499 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Monte Rosa Therapeutics by 54.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 24,100 shares of the company’s stock worth $128,000 after purchasing an additional 8,500 shares in the last quarter. JPMorgan Chase & Co. grew its position in Monte Rosa Therapeutics by 38.2% during the third quarter. JPMorgan Chase & Co. now owns 18,543 shares of the company’s stock valued at $98,000 after purchasing an additional 5,125 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in Monte Rosa Therapeutics by 14.8% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 117,877 shares of the company’s stock valued at $625,000 after buying an additional 15,168 shares during the period. Institutional investors and hedge funds own 79.96% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on GLUE. Lifesci Capital initiated coverage on shares of Monte Rosa Therapeutics in a research note on Wednesday, March 12th. They set an “outperform” rating and a $19.00 target price for the company. Wells Fargo & Company decreased their price target on shares of Monte Rosa Therapeutics from $11.00 to $10.00 and set an “equal weight” rating for the company in a report on Friday, March 21st. Finally, Wedbush reiterated an “outperform” rating and set a $17.00 target price (up from $15.00) on shares of Monte Rosa Therapeutics in a research note on Thursday, March 20th.

Insider Transactions at Monte Rosa Therapeutics

In related news, Director Chandra P. Leo purchased 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 24th. The shares were acquired at an average price of $5.84 per share, with a total value of $58,400.00. Following the purchase, the director now directly owns 10,000 shares in the company, valued at $58,400. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 6.50% of the stock is owned by insiders.

Monte Rosa Therapeutics Stock Down 3.0 %

Monte Rosa Therapeutics stock opened at $5.10 on Friday. The business has a 50 day moving average price of $6.15 and a two-hundred day moving average price of $6.76. Monte Rosa Therapeutics, Inc. has a 12 month low of $3.21 and a 12 month high of $12.40. The stock has a market cap of $313.70 million, a price-to-earnings ratio of -2.79 and a beta of 1.50.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its earnings results on Thursday, March 20th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of ($0.37) by $0.60. The firm had revenue of $14.00 million during the quarter, compared to the consensus estimate of $43.73 million. On average, analysts expect that Monte Rosa Therapeutics, Inc. will post -1.49 earnings per share for the current fiscal year.

Monte Rosa Therapeutics Profile

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.